GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (OTCPK:WUXAY) » Definitions » Net Intangibles Purchase And Sale

WUXAY (Wuxi AppTec Co) Net Intangibles Purchase And Sale : $0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Wuxi AppTec Co Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Wuxi AppTec Co's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $0 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2025 was $0 Mil.

Wuxi AppTec Co Net Intangibles Purchase And Sale Historical Data

The historical data trend for Wuxi AppTec Co's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co Net Intangibles Purchase And Sale Chart

Wuxi AppTec Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Wuxi AppTec Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Wuxi AppTec Co Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuxi AppTec Co Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuxi AppTec Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (OTCPK:WUXAY) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
SZSE:300347 SZSE:300676 SHSE:603882 SHSE:603127 SHSE:603108 SZSE:300244 SZSE:300685 SZSE:300406 SZSE:300463 SZSE:000710 TMO DHR XSWX:LONN IDXX A IQV MTD NTRA WAT DGX
Traded in Other Exchanges
WUXIF:USA 02359:Hong Kong WX8:Germany 603259:China
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, CHN, 200131
Website
https://www.wuxiapptec.com
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by China, Europe, and other regions.